From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass145.3 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]

See also[edit]


  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
  2. ^ Rossi, E. A.; Goldenberg, D. M.; Cardillo, T. M.; Stein, R.; Chang, C. -H. (2009). "CD20-targeted tetrameric interferon- , a novel and potent immunocytokine for the therapy of B-cell lymphomas". Blood. 114 (18): 3864–71. doi:10.1182/blood-2009-06-228890. PMC 2773491. PMID 19710501.
  3. ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at
  4. ^ Christian, BA; Poi, M; Jones, JA; Porcu, P; Maddocks, K; Flynn, JM; Benson, DM Jr; Phelps, MA; Wei, L; Byrd, JC; Wegener, WA; Goldenberg, DM; Baiocchi, RA; Blum, KA (2015). "The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma". Br J Haematol. 169 (5): 701–10. doi:10.1111/bjh.13354. PMID 25847298.
  5. ^ Handbook of Therapeutic Antibodies. p791
  6. ^ a b FDA grants orphan drug designation to veltuzumab for ITP